Work

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Year: 2023

Type: article

Abstract: Teclistamab (Tecvayli®) is a first-in-class T-cell redirecting bispecific antibody that targets CD3 on the surface of T-cells and B-cell maturation antigen (BCMA) on plasma cells [ 1 ]. Teclistamab was approved by the FDA for patients with relapsed/refractory multiple myeloma (RRMM) after 4 lines of therapy including an immunomodulatory drug (IMID), proteasome inhibitor (PI), and anti-CD38 monoclonal antibody (mAb) based on the results of the phase 1/2 MajesTEC-1 study. Among the 165 patients treated with teclistamab, the overall response rate (ORR) was 63% with 58.8% of patients achieving a very good partial response (VGPR) or better. The median duration of response (DOR) was 18.4 months, median progression free survival (PFS) was 11.3 months, and median overall survival (OS) was 18.3 months [ 2 ].

Source: Blood Cancer Journal

DOI: 10.1038/s41408-023-00963-y